Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 13/20 | 0.60 |
| ▸ | CA2 | P00918 | 13/20 | 0.60 |
| ▸ | CA1 | P00915 | 12/20 | 0.60 |
| ▸ | CA12 | O43570 | 11/20 | 0.60 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25783041 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL15247399 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL12935270 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL25721435 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL13464528 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL7146506 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL185606 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL2736530 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL18391019 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL14923179 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253524-B2 | Metabolites of bictegravir | GILEAD SCIENCES, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2019144015-A1 | METABOLITES OF BICTEGRAVIR | GILEAD SCIENCES, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190224206-A1 | METABOLITES OF BICTEGRAVIR | GILEAD SCIENCES, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10183997-B2 | Compositions and methods related to anti-CD19 antibody drug conjugates | LEGOCHEM BIOSCIENCES, INC. (KR) | 2019-01-22 | — | — | US | disclosed |
| US-20180030078-A1 | A NEW QUINOLINE DERIVATIVE FOR USE IN THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | UNIVERSITE DE MONTPELLIER (FR) | 2018-02-01 | — | — | US | disclosed |
| US-9669107-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-06 | — | — | US | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| EP-3156424-A1 | COMPOUND CONTAINING SELF-IMMOLATIVE GROUP | LegoChem Biosciences, Inc. (KR) | 2017-04-19 | — | — | EP | disclosed |
| US-20170095576-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-04-06 | — | — | US | disclosed |
| EP-2155769-A2 | TISSUE DEGENERATION PROTECTION | Katholieke Universiteit Leuven (BE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008134828-A2 | TISSUE DEGENERATION PROTECTION | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008083312-A2 | CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20040167080-A1 | Glucopyranoside benzothiophenes | DODGE JEFFREY A (US) | 2004-08-26 | — | — | US | disclosed |
| US-6723739-B1 | INHIBITING POSTMENOPAUSAL OSTEOPOROSIS | ELI LILLY AND COMPANY | 2004-04-20 | — | — | US | disclosed |
| EP-0683170-B1 | Glucopyranoside benzothiophenes | LILLY CO ELI (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5567820-A | THERAPY FOR BONE DISEASES | ELI LILLY AND COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0683170-A1 | Glucopyranoside benzothiophenes | ELI LILLY AND COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| EP-0018063-B1 | PYRIDAZIN (2H)-3-ONES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN ANTIHYPERTENSIVE AGENTS | DIAMOND SHAMROCK CORPORATION (US) | 1983-02-23 | — | — | EP | disclosed |
| US-4238490-A | Antihypertensive pyridazin(2H)-3-ones | DIAMOND SHAMROCK CORPORATION (US) | 1980-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183997-B2 | Compositions and methods related to anti-CD19 antibody drug conjugates | CD47, CD22, BCL6 | CA9 93/4885CA2 856/4885CA1 187/4885 |
| US-11253524-B2 | Metabolites of bictegravir | CYP3A43, CYP3A4, CYP3A5 | CA9 2836/4885CA2 4242/4885CA1 4696/4885 |
| US-20040167080-A1 | Glucopyranoside benzothiophenes | UGGT1, SLC5A1, B4GALT1 | CA9 2203/4885CA2 2411/4885CA1 3136/4885 |
| US-20170095576-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | IAPP, IDE, DNPEP | CA9 722/4885CA2 1663/4885CA1 420/4885 |
| US-20190224206-A1 | METABOLITES OF BICTEGRAVIR | CYP3A43, CYP3A4, CYP3A5 | CA9 2836/4885CA2 4242/4885CA1 4696/4885 |
| US-20180030078-A1 | A NEW QUINOLINE DERIVATIVE FOR USE IN THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | MAVS, NQO2, IRF3 | CA9 4751/4885CA2 4387/4885CA1 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.